Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DPX-Survivac and Pembrolizumab in Relapsed/Refractory DLBCL
NCT04920617Phase 2Recruiting
- Sponsor
- ImmunoVaccine Technologies Inc.
- Start
- Jun 2021
- Primary completion
- Oct 2024
- Modality
- Peptides, Vaccines & Immunotherapeutics
- Countries
- 10
01
Overview
Phase 2, randomised, open-label trial of maveropepimut-S in diffuse large B-cell lymphoma (DLBCL) (2 arms), sponsored by ImmunoVaccine Technologies Inc. Primary endpoint: Objective Response Rate at 24 months. Started Jun 2021; status: recruiting.
02
Drugs
maveropepimut-S
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT04920617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04920617.